Netherton syndrome: Temporary response to dupilumab
PEDIATRIC DERMATOLOGY, vol.37, no.6, pp.1210-1211, 2020 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 37 Issue: 6
- Publication Date: 2020
- Doi Number: 10.1111/pde.14362
- Journal Name: PEDIATRIC DERMATOLOGY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE
- Page Numbers: pp.1210-1211
- Keywords: atopic eczema, genetic diseases, mechanisms, Ichthyosis
- Acibadem Mehmet Ali Aydinlar University Affiliated: No
Abstract
Netherton syndrome (NS) is an orphan disease characterized by congenital ichthyosis, hair abnormalities, and atopy, with limited treatment options. We achieved temporary improvement only during the initial 6 weeks of treatment with dupilumab, which differs from the sustained improvement observed in 2 other recently published cases. Although the clinical presentation of atopy and increased pre-allergic cytokines in NS patients suggest that dupilumab may be beneficial, larger studies are required.